Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Want to cut your energy bills? Here’s how five experts are doing it 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
MENLO PARK, Calif., May 30, 2017 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Jefferies 2017 Global Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Tuesday, June 6, 2017, in New York.
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), which has completed a Phase 3 program for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil (formerly DRM01), in Phase 3 development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Ian Clements, Ph.D. Vice President, Investor Relations 650-422-7753 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 [email protected]
